Female Viagra – Flibanserin – is finally here and set to ignite bedrooms by increasing women’s sex drives. Eighteen panelists of the the U.S. Food and Drug Administration gave the new drug their blessings on the condition that strict measures are adhered to.

Experts believe that the benefits of the drug are marginal, but meaningful enough for them to give their approval so as to help sex-starved women rekindle their lust. The panel was persuaded by dozens of women who spoke about the distress caused by their low sex drive. Moved by these confessions the panel decided to take the risk and approve the drug under the proposed name Addyi. It will help women feel some desire, but the side effects include fainting at unpredictable times (eg. behind the wheel of a car), accidental injury and low blood pressure.

The difference between female Viagra and the male kind is that Flibanserin works on the brain while Viagra, available for males since 1998, affects blood flow to the genitals. First developed as an anti-depressent by Boehringer Ingelheim, Flibanswerin will need to be taken daily for women’s sex drive to increase.

FILE – In this Friday, Sept. 27, 2013, file photo, a tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals in the company’s Raleigh, N.C., headquarters. Government health experts on Thursday, June 4, 2015 backed the approval of the experimental drug intended to boost the female sex drive, but stress that it should carry safety restrictions to manage side effects including fatigue, low blood pressure and fainting. (AP Photo/Allen G. Breed, File)